MUTYH and cancer: A possible explanation of the more severe clinical phenotype detected in patients concurrently harboring both genetic alterations is that monoallelic MUTYH c.536A>G pathogenic variants, which reduce the glycosylase activity of the protein, can lead to the early accumulation of errors in cancer driver genes.